<p>EAE was assessed fourteen days after C57BL/6 mice were immunized with MOG peptide<sub>35<b>–</b>55</sub>, CFA and PTX or immunized and a footpad challenged with intradermal MOG peptide<sub>35<b>–</b>55</sub> or IRBP peptide<sub>161<b>–</b>180</sub> 7 days P.I. Following immunization, animals were kept under observation to score the disease. The study was done in a blinded fashion. The EAE scale was as follows: 0 = normal, 1 = limp tail, 2 = paraparesis with a clumsy gait, 3 = hind limb paralysis, 4 = quadriplegia, 5 = death. Data represents the mean score +/− S.E.M. of five mice/point. The experiment was done twice. DTH: delayed type hypersensitivity, chl: challenge</p
<p>Data correspond to those illustrated in <a href="http://www.plosone.org/article/info:doi/10.1371/...
<p>(<b>A - right</b>) Time course of clinical signs recorded from Panx1 wild type (WT) and Panx1 kno...
<p>(<b>A</b>) Disease scores are shown for EAE in B6 mice at various time points after subcutaneous ...
<p>Clinical scores in wild-type mice and <i>Ptprz</i>-deficient mice after the MOG peptide injection...
<p>(A): Wild-type (WT, n = 16) and t-PA<sup>-/-</sup> mice (n = 9) were immunized with the MOG<sub>3...
<p>Paralysis in EAE-affected mice was assessed by clinical scoring up to 23 days post-immunisation. ...
<p>Female C57BL/6 wild-type mice were immunized with MOG35-55 to induce paralyzed EAE. PBS, excess M...
<p><b>(A)</b> Mean clinical score of four independent experiments testing the preventive potential o...
<p>(<b>A</b>) EAE was induced by immunization with MOG<sub>35–55</sub> peptide and animals were scor...
<p>Paralysis in EAE-affected mice was assessed by clinical scoring up to 20 days post-immunisation. ...
<p><b>A</b>, EAE was induced in <i>Was</i><sup>−<i>/</i>−</sup> (<i>white circles</i>) and WT mice (...
<p>Data correspond to those illustrated in <a href="http://www.plosone.org/article/info:doi/10.1371/...
<p>(A) EAE was induced in mice by immunization with MOG<sub>35-55</sub> peptide, using either 50 μg ...
<p>(A) <i>WASH<sup>f/f</sup> CD11c-Cre</i> mice and control <i>WASH<sup>f/f</sup></i> mice were immu...
<p>EAE was induced by active immunization at 2 sites with MOG peptide<sup>35–55</sup> emusified in C...
<p>Data correspond to those illustrated in <a href="http://www.plosone.org/article/info:doi/10.1371/...
<p>(<b>A - right</b>) Time course of clinical signs recorded from Panx1 wild type (WT) and Panx1 kno...
<p>(<b>A</b>) Disease scores are shown for EAE in B6 mice at various time points after subcutaneous ...
<p>Clinical scores in wild-type mice and <i>Ptprz</i>-deficient mice after the MOG peptide injection...
<p>(A): Wild-type (WT, n = 16) and t-PA<sup>-/-</sup> mice (n = 9) were immunized with the MOG<sub>3...
<p>Paralysis in EAE-affected mice was assessed by clinical scoring up to 23 days post-immunisation. ...
<p>Female C57BL/6 wild-type mice were immunized with MOG35-55 to induce paralyzed EAE. PBS, excess M...
<p><b>(A)</b> Mean clinical score of four independent experiments testing the preventive potential o...
<p>(<b>A</b>) EAE was induced by immunization with MOG<sub>35–55</sub> peptide and animals were scor...
<p>Paralysis in EAE-affected mice was assessed by clinical scoring up to 20 days post-immunisation. ...
<p><b>A</b>, EAE was induced in <i>Was</i><sup>−<i>/</i>−</sup> (<i>white circles</i>) and WT mice (...
<p>Data correspond to those illustrated in <a href="http://www.plosone.org/article/info:doi/10.1371/...
<p>(A) EAE was induced in mice by immunization with MOG<sub>35-55</sub> peptide, using either 50 μg ...
<p>(A) <i>WASH<sup>f/f</sup> CD11c-Cre</i> mice and control <i>WASH<sup>f/f</sup></i> mice were immu...
<p>EAE was induced by active immunization at 2 sites with MOG peptide<sup>35–55</sup> emusified in C...
<p>Data correspond to those illustrated in <a href="http://www.plosone.org/article/info:doi/10.1371/...
<p>(<b>A - right</b>) Time course of clinical signs recorded from Panx1 wild type (WT) and Panx1 kno...
<p>(<b>A</b>) Disease scores are shown for EAE in B6 mice at various time points after subcutaneous ...